Dapagliflozin: A Game Changer In Managing Type 2 Diabetes - Ayu Health
Dapagliflozin use in type 1 diabetes: industry, business and ethics | British Journal of Diabetes
Dapagliflozin withdrawn for type 1 diabetes – EASD e-Learning
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials - The Lancet Diabetes & Endocrinology
Dapagliflozin improves glucose outcomes in type 1 diabetes
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial - The Lancet Diabetes & Endocrinology
SGLT inhibitors for type 1 diabetes: a finely balanced matter?
Diabetes type 1 treatment: AstraZeneca's Forxiga has gained approval
Our response to the withdrawal of dapagliflozin (Forxiga) for type 1 diabetes - JDRF, the type 1 diabetes charity
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination – touchENDOCRINOLOGY
Dapagliflozin effective in treating type 1 diabetes
Effects of dapagliflozin on renal function in type 1 diabetes patients in the real world: a retrospective multicenter study of the KAMOGAWA-A cohort - Diabetes Research and Clinical Practice
JDRF Reports: European Commission Has Approved Forxiga for T1D
Zulassungsempfehlung : Dapagliflozin als erste orale Add-on-Therapie bei Typ -1-Diabetes
Pharmaceuticals | Free Full-Text | The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
Exploring the potential of dapagliflozin in type 1 diabetes: phase 2a pilot study - Media Centre | EASD
Rote-Hand-Brief zu Forxiga - coliquio
Medicina | Free Full-Text | Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report
Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta‑analysis of randomized controlled trials
Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks | Drug and Therapeutics Bulletin
Diabetische Ketoazidose unter Forxiga: Dapagliflozin verliert seine Typ-1- Diabetes-Indikation
Dapagliflozin: An effective adjunctive treatment in type 1 diabetes - DiabetesontheNet
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks - The Lancet Diabetes & Endocrinology
